

PATENT Docket No. 415072000100

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: COMPOSITIONS AND METHODS FOR GENERATING MONOCLONAL ANTIBODIES REPRESENTATIVE OF A SPECIFIC CELL TYPE, the specification of which is attached hereto unless the following box is checked:

was filed on	as United States Application Serial No.		
and was amended on	· · · · · · · · · · · · · · · · · · ·		
	·=		


I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Billing (day/month/year)	Priority (Ceilmed?
·			□Yes	□No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:



I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

#

Application Serial Nove	IffilmgiDate	Stains	
			□Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Besidence:

Jeannie P. Mathe

U.S.A.

U.S.A.

269 La Prenda Drive, Millbrae, California 94030

Citizenship:

Post Office Address:

269 La Prenda Drive, Millbrae, California 94030

Name:

Laura N. Bald

Residence:

278 Senna Court, Sunnyvale, California 94086

Citizenship:

Post Office Address:

278 Senna Court, Sunnyvale, California 94086

Name:

Penelope E. Roberts

Residence:

269 La Prenda Drive, Millbrae, California 94030

Citizenship:

U.S.A. Post Office Address:

269 La Prenda Drive, Millbrae, California 94030

Residence:

Townsquare, 320C Lansdale Avenue, Millbrae, California 94030

Citizenship:

Post Office Address:

Townsquare, 320C Lansdale Avenue, Millbrae, California 94030

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number. Docket No. (Optional) PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) 415072000110 In re Application of Jennie P. MATHER et al. Application Number Filed 09/614,483 July 10, 2000 COMPOSITIONS AND METHODS FOR GENERATING MONOCLONAL ANTIBODIES REPRESENTATIVE OF A For: SPECIFIC CELL TYPE Art Unit G. Ewoldt Examiner 1644 This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application. The requested extension and appropriate non-small-entity fee are as follows (check time period desired): One month (37 CFR 1.17(a)(1)) Two months (37 CFR 1.17(a)(2)) \$ Three months (37 CFR 1.17(a)(3))-\$ \$ Four months (37 CFR 1.17(a)(4)) Five months (37 CFR 1.17(a)(5)) 1,970.00 Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ 985.00 A check in the amount of the fee is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director has already been authorized to charge fees in this application to a Deposit Account. The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 03-1952 Lhave enclosed a duplicate copy of this sheet. Fee Transmittal Form (PTO/SB/17) is attached to this submission in duplicate. I am the applicant/inventor. assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). attorney or agent of record. Registration Number 52,395 attorney or agent under 37 CFR 1.34(a). Registration number if acting under 37 CFR 1.34(a) September 26, 2003 Signature Date (650) 813-5922 Jie Zhou, Reg. No. 52,395 Telephone Number Typed or printed name NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below х Total of forms are submitted.